Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports.
Three patients with cerebral palsy are described suffering, respectively, of pes equinus, spasm of the m. teres major and flexion spasm of the hand, who were treated with botulinum toxin A. These patients demonstrate not only the local reduction of the muscular hyperactivity following treatment with botulinum toxin A but also the potential functional benefit resulting from such a treatment. Thus, local intramuscular injection of botulinum toxin A in children with cerebral palsy should be considered as part of a multidisciplinary treatment concept, since reduction of the disability and the functional improvements could have high impact on daily living activities.
Mall
V
V
Department of Neuropediatrics, Children's Hospital, University of Freiburg, Germany.
Heinen
F
F
Linder
M
M
Philipsen
A
A
Korinthenberg
R
R
D000203:Activities of Daily Living; D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000503:physiopathology / Q000628:therapy*; D003286:Contracture / Q000628:therapy; D004863:Equinus Deformity / Q000628:therapy; D005260:Female; D005684:Gait / Q000502:physiology; D006225:Hand / Q000503:physiopathology; D006801:Humans; D007273:Injections, Intramuscular; D004204:Joint Dislocations / Q000628:therapy; D008297:Male; D009128:Muscle Spasticity / Q000628:therapy; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012785:Shoulder Joint / Q000503:physiopathology; D012890:Sleep / Q000502:physiology; D016138:Walking / Q000502:physiology
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A